The evolving background for high-dose treatment for myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Autologous stem cell transplantation (ASCT) has been a cornerstone in multiple myeloma treatment for 25 years, significantly improving survival.
• The advent of novel targeted therapies presents a challenge in optimizing ASCT protocols.
• Established targeted treatments include Thalidomide, Revlimid (Lenalidomide), and Velcade (Bortezomib).

Purpose of the Study:

• To examine the integration of newer targeted treatments with ASCT strategies in multiple myeloma.
• To emphasize achieving long-term survival and high quality of life for patients.
• To define the concept of 'operational cure' in the context of myeloma management.

Main Methods:

• Review of current literature and clinical practices regarding ASCT and targeted therapies for multiple myeloma.
• Analysis of treatment strategies focusing on optimizing patient outcomes.
• Discussion of the role of novel agents in conjunction with transplantation.

Main Results:

• ASCT has demonstrably improved complete remission rates and doubled survival in multiple myeloma patients.
• Newer targeted therapies are being integrated to refine ASCT's role and enhance patient outcomes.
• The concept of 'operational cure' suggests achieving a state where molecular disease is undetectable, allowing for a normal quality of life.

Conclusions:

• Optimizing the use of targeted therapies alongside ASCT is crucial for advancing multiple myeloma treatment.
• The focus is shifting towards achieving long-term, functional survival rather than complete eradication of all disease.
• This special issue aims to guide clinicians in managing patients and stimulate further research for improved myeloma outcomes.